Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J Costa, MD PhD, Edward A. Stadtmauer, MD FACP, Gareth Morgan, MD, Gregory Monohan, MD, Tibor Kovacsovics, MD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Mehrdad Mobasher, MD MPH, Kevin J. Freise, PhD, Jeremy A. Ross, PhD, John Pesko, PhD, Wijith Munasinghe, PhD, Saketh Gudipati, MD, Sarah Mudd, PhD, Orlando Bueno, MD PhD, Shaji K. Kumar, MD

Blood (2018) 132 (Supplement 1): 303.

https://doi.org/10.1182/blood-2018-99-117026

Published: 2018

Journal Articles

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Avrita Campinha-Bacote, Wan-Jen Hong, Patrick Phuong, Jue Wang, Mehrdad Mobasher, MD MPH, Peter Trask

Blood (2018) 132 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2018-99-116038

Published: 2018

Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Blood (2018) 132 (Supplement 1): 782.

https://doi.org/10.1182/blood-2018-99-118519

Published: 2018

Journal Articles

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P. Kater, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, MD PhD, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, MD MPH, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 185.

https://doi.org/10.1182/blood-2018-99-117050

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD PhD, Matthew S Davids, Julie Chang, Shuo Ma, MD PhD, Juliana Biondo, Mehrdad Mobasher, MD MPH, Yong Mun, PhD, Anthony R Mato, MD

Blood (2018) 132 (Supplement 1): 5556.

https://doi.org/10.1182/blood-2018-99-116942

Published: 2018

Journal Articles

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

Blood (2018) 132 (Supplement 1): 767.

https://doi.org/10.1182/blood-2018-99-116013

Published: 2018

Journal Articles

Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, Guillaume Cartron, Michael Hallek, Barbara Eichhorst, Mark F. Kozloff, Thomas Giever, Gerard Lozanski, MD, Yanwen Jiang, Huang Huang, Daniela Soriano Pignataro, William Schary, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Gilles Salles, MD PhD

Blood (2018) 132 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2018-99-118362

Published: 2018

Journal Articles

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Iris de Weerdt, MD, Tom Hofland, MSc, Johan Dobber, Julie Dubois, Eric Eldering, PhD, Mehrdad Mobasher, MD MPH, Fransien Croon-de Boer, Mels Hoogendoorn, MD PhD, Gerjo A. Velders, PhD MD, Marjolein van der Klift, Mark-David Levin, MD PhD, Sabina Kersting, MDPhD, Sanne Tonino, MD PhD, Arnon P. Kater, MD

Blood (2018) 132 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2018-99-116283

Published: 2018

Journal Articles

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Blood (2018) 132 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2018-99-116806

Published: 2018

Journal Articles

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2018) 132 (Supplement 1): 184.

https://doi.org/10.1182/blood-2018-184

Published: 2018

Journal Articles

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

Blood (2017) 130 (Supplement 1): LBA-2.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-2.LBA-2

Published: 2017

Journal Articles

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Andrew D Zelenetz, MD, PhD, Mehrdad Mobasher, MD, MPH, Luciano J Costa, MD, PhD, Ian Flinn, MD, PhD, Christopher R. Flowers, MD, MS, Mark S. Kaminski, MD, Thomas Sandmann, PhD, Kerstin Trunzer, PhD, Charlotte Vignal, MSc, PhD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 1820.

https://doi.org/10.1182/blood.V122.21.1820.1820

Published: 2013

NARROW

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only